Menarini Granted Exclusive Distribution Rights to Boditech’s AFIAS-10

After a number of years working together, A.Menarini Diagnostics and Boditech Med have announced a new collaborative partnership regarding the exclusive distribution of the IGRA-TB test and AFIAS-10 software.

Menarini will instantly be able to start selling the AFIAS-10 products to 34 European nations.

This is a completely automated diagnostic system that can run ten tests concurrently without any intervention. It has a simple testing process that uses blood collection vials and performs a number of examinations. This yields fast outcomes and enables the speedy transfer of medical data.

IGRA-TB is used to measure the amount of interferon gamma (IFN-) that human blood cells release when they have been exposed to Mycobacterium tuberculosis (MTB) antigens. The AFIAS IGRA-TB assay is a straightforward, quick, and relatively inexpensive fluorescence immunoassay.

The International Head of Menarini Diagnostics, Fabio Piazzalunga, said that “this agreement represents a great opportunity for our Company to contribute to the required efficiency of IVD services by bringing a highly innovative system for the immuno-assay single test market onto the EU market, being Afias-10 a perfect fit for decentralized use with cost effective positioning”.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.